Carregant...
Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity
Inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinases,such as erlotinib and gefitinib, have not been very effective in the treatment of breast cancer although many breast cancer cells express EGFR. To address this apparent paradox, we examined possible predictors of the sensitivity...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2007
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2603172/ https://ncbi.nlm.nih.gov/pubmed/17671085 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-06-0514 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|